The Manila Times

Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist

The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indicationsAllschwil, Switzerland - January 6, 2026 ...

Hyundai and Boston Dynamics unveil humanoid robot Atlas at CES

Boston Dynamics said a product version of the robot that will help assemble cars is already in production and will be ...
PCMag on MSN

Intel's 'Panther Lake' Core Ultra Laptop Chips Are Ready for Prime Time: All the Details We Know So Far

At CES, Intel details its launch lineup for the new Core Ultra Series 3 processors (based on its 2nm 18A architecture) that ...
eLife

Separating selection from mutation in antibody language models

This important study introduces a new biology-informed strategy for deep learning models aiming to predict mutational effects in antibody sequences. It provides solid evidence that separating ...

Idorsia Pharmaceuticals Ltd: Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist

The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indications Allschwil, Switzerland - January 6, 2026Idorsia ...